PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35426448-3	2022	Pegylated liposomal doxorubicin (PEG-DOXO) is an anthracycline used in the management of advanced primary CTCL, particularly in induction strategies.	liposomal doxorubicin	33-41	TSPY like 2	Homo sapiens	106-110	
18559761-1	2008	OBJECTIVE: To assess the rate of objective response to pegylated liposomal doxorubicin hydrochloride (Caelyx) in patients with advanced or refractory cutaneous T-cell lymphoma (CTCL).	liposomal doxorubicin	102-108	TSPY like 2	Homo sapiens	177-181	
18559761-10	2008	CONCLUSIONS: This prospective study demonstrates the effectiveness of Caelyx in treating CTCL, with an overall response rate of 56% in spite of the high proportion of patients with advanced-stage disease.	liposomal doxorubicin	70-76	TSPY like 2	Homo sapiens	89-93	
12942567-1	2003	BACKGROUND: In single center studies and case reports, it was shown that pegylated liposomal doxorubicin (PEG-DOXO) was effective as second-line therapy for patients with cutaneous T-cell lymphoma (CTCL).	liposomal doxorubicin	106-114	TSPY like 2	Homo sapiens	198-202	
12942567-2	2003	The objective of this study was to evaluate the efficacy and toxicity of single-agent PEG-DOXO as second-line chemotherapy in patients with CTCL.	liposomal doxorubicin	86-94	TSPY like 2	Homo sapiens	140-144	
12942567-16	2003	CONCLUSIONS: This multicenter study provided evidence of high efficacy of PEG-DOXO monotherapy with a low rate of severe adverse effects compared with other chemotherapy protocols in patients with CTCL.	liposomal doxorubicin	74-82	TSPY like 2	Homo sapiens	197-201	
11216914-1	2001	PURPOSE: Pegylated liposomal doxorubicin (PEG-DOXO) was found to be effective in primary cutaneous T-cell lymphomas (CTCL).	liposomal doxorubicin	42-50	TSPY like 2	Homo sapiens	117-121	
11216914-15	2001	Another patient died 1 month after a second course of PEG-DOXO in an advanced tumor stage of CTCL.	liposomal doxorubicin	54-62	TSPY like 2	Homo sapiens	93-97	
11216914-18	2001	CONCLUSIONS: These results indicate that patients with relapsing or recalcitrant CTCL can achieve an 80% response rate with PEG-DOXO and long-term remissions.	liposomal doxorubicin	124-132	TSPY like 2	Homo sapiens	81-85